Company intelligence / Profile preview

AKL Research & Development Limited

Stevenage, England, United Kingdomakltherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

APPA, the lead asset, is an oral fixed-dose combination of two synthetically produced secondary metabolites of plant origin. In a Phase 2a trial for osteoarthritis, APPA demonstrated a good safety profile and statistically significant pain reduction versus placebo in patients with more severe disease. The company is currently raising funds for a Phase 2b trial targeting this patient group. APPA has also been granted an Innovation Passport by the UK MHRA.[7]

Therapeutic areas: PulmonologyRheumatologyNeurology
Modalities: Small molecules (specifically, secondary metabolites of plant origin)[6][7]
Industry: Biotech

Drug pipeline

2 assets

APPA

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AKL Research & Development Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKL Research & Development Limited.

Explore the full profile